These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 21622725)

  • 1. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
    Allen E; Walters IB; Hanahan D
    Clin Cancer Res; 2011 Aug; 17(16):5299-310. PubMed ID: 21622725
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
    Huynh H; Ngo VC; Fargnoli J; Ayers M; Soo KC; Koong HN; Thng CH; Ong HS; Chung A; Chow P; Pollock P; Byron S; Tran E
    Clin Cancer Res; 2008 Oct; 14(19):6146-53. PubMed ID: 18829493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
    Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
    J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases.
    Bhide RS; Lombardo LJ; Hunt JT; Cai ZW; Barrish JC; Galbraith S; Jeyaseelan R; Mortillo S; Wautlet BS; Krishnan B; Kukral D; Malone H; Lewin AC; Henley BJ; Fargnoli J
    Mol Cancer Ther; 2010 Feb; 9(2):369-78. PubMed ID: 20103604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
    Chiu CW; Nozawa H; Hanahan D
    J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beneficial effects of dual vascular endothelial growth factor receptor/fibroblast growth factor receptor inhibitor brivanib alaninate in cirrhotic portal hypertensive rats.
    Lin HC; Huang YT; Yang YY; Lee PC; Hwang LH; Lee WP; Kuo YJ; Lee KC; Hsieh YC; Liu RS
    J Gastroenterol Hepatol; 2014 May; 29(5):1073-82. PubMed ID: 24325631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
    Fendrich V; Maschuw K; Rehm J; Buchholz M; Holler JP; Slater EP; Bartsch DK; Waldmann J
    ScientificWorldJournal; 2012; 2012():529151. PubMed ID: 23346016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
    Yang YY; Liu RS; Lee PC; Yeh YC; Huang YT; Lee WP; Lee KC; Hsieh YC; Lee FY; Tan TW; Lin HC
    Liver Int; 2014 Apr; 34(4):521-34. PubMed ID: 23998651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
    Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
    Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade.
    Rigamonti N; Kadioglu E; Keklikoglou I; Wyser Rmili C; Leow CC; De Palma M
    Cell Rep; 2014 Aug; 8(3):696-706. PubMed ID: 25088418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
    Yang Y; Jiang H; Gao H; Kong J; Zhang P; Hu S; Shi B; Zhang P; Yao M; Li Z
    Neoplasia; 2012 Jun; 14(6):509-18. PubMed ID: 22787432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapy in HCC: lessons from brivanib.
    Bolos D; Finn RS
    J Hepatol; 2014 Oct; 61(4):947-50. PubMed ID: 24972045
    [No Abstract]   [Full Text] [Related]  

  • 14. CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    Devapatla B; Sharma A; Woo S
    PLoS One; 2015; 10(9):e0139237. PubMed ID: 26414070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
    Tang TC; Man S; Xu P; Francia G; Hashimoto K; Emmenegger U; Kerbel RS
    Neoplasia; 2010 Nov; 12(11):928-40. PubMed ID: 21076618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors.
    Patel RR; Sengupta S; Kim HR; Klein-Szanto AJ; Pyle JR; Zhu F; Li T; Ross EA; Oseni S; Fargnoli J; Jordan VC
    Eur J Cancer; 2010 Jun; 46(9):1537-53. PubMed ID: 20303261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist.
    Ayers M; Fargnoli J; Lewin A; Wu Q; Platero JS
    Cancer Res; 2007 Jul; 67(14):6899-906. PubMed ID: 17638901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
    Jilaveanu L; Zito C; Lee SJ; Nathanson KL; Camp RL; Rimm DL; Flaherty KT; Kluger HM
    Clin Cancer Res; 2009 Feb; 15(3):1076-85. PubMed ID: 19188183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brivanib: a review of development.
    Chou T; Finn RS
    Future Oncol; 2012 Sep; 8(9):1083-90. PubMed ID: 23030483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brivanib attenuates hepatic fibrosis in vivo and stellate cell activation in vitro by inhibition of FGF, VEGF and PDGF signaling.
    Nakamura I; Zakharia K; Banini BA; Mikhail DS; Kim TH; Yang JD; Moser CD; Shaleh HM; Thornburgh SR; Walters I; Roberts LR
    PLoS One; 2014; 9(4):e92273. PubMed ID: 24710173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.